摘要
乙型肝炎病毒(hepatitis B virus,HBV)属于嗜肝DNA病毒科,其感染易慢化。若慢性感染HBV得不到及时有效的治疗,有进一步发展为肝硬化甚至肝癌等终末期肝病的风险。HBV难以治愈的主要原因是共价闭合环状DNA(cccDNA)难以彻底清除以及病毒引发的免疫耐受,目前,临床常用的核苷(酸)类似物与聚乙二醇干扰素疗法无法实现乙肝表面抗原(HBsAg)清除以及病毒复制的完全抑制,因此,开发新型抗HBV药物尤为重要紧迫。文章主要从降低HBsAg水平、抑制HBV复制和恢复宿主免疫反应等三个方面,综合阐述了乙型肝炎病毒新型药物的研发现状,旨在为HBV患者的临床治疗提供有力参考。
Hepatitis B virus(HBV)belong to the hepatophil DNA virus family and its infection is prone to become chronic.The chronic HBV infection is at the risk of further progession to cirrhosis and even hepatocellular carcinoma.The main reason why HBV is difficult to cure are the persistence of covalently closed circular DNA(cccDNA)and virus-induced immune tolerance.At present,nucleoside(acid)analogues and pegylated interferon therapy commonly used in clinical practice cannot achieve hepatitis B surface antigen(HBsAg)clearance and complete inhibition of viral replication.Therefore,the development of novel drugs for HBV is considered particularly important and urgent.The research and development status of new drugs for hepatitis B is mainly summarized from three aspects,including reducing HBsAg level,inhibiting HBV replication and restoring host immune response in this paper,in order to provide a strong reference for clinical treatment of HBV patients.
作者
罗恩慧
张德燚
窦洁
郭敏
罗珍
LUO Enhui;ZHANG Deyi;DOU Jie;GUO Min;LUO Zhen(College of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,China;Xizang University of Tibetan Medicine,Lhasa 850007,China)
出处
《药物生物技术》
2025年第5期697-702,共6页
Pharmaceutical Biotechnology
基金
2024年藏医药基础教育部重点实验室开放课题(No.ZYYJC-24-04)。
